Literature DB >> 2111774

Effects of taprostene, a stable prostacyclin analogue, on haemodynamics, platelet function and arachidonate metabolism in healthy volunteers.

I Virgolini1, P Fitscha, H Sinzinger, H Barth.   

Abstract

In order to assess the effect of taprostene on haemodynamics, platelet function and arachidonate metabolism in 4 healthy volunteers an intravenous infusion of 25 ng.kg-1.min-1 was given for 6 h. During the infusion period systolic blood pressure dropped from 130 to 111 mm Hg and diastolic blood pressure from 77 to 69 mm Hg. The heart rate rose from 77 to 84 beats/min. During the taprostene infusion the slope and height of the ADP and collagen induced platelet aggregation curves were significantly inhibited and the sensitivity of platelets to PGI2 and PGE1 was increased. Plasma and serum thromboxane B2, conversion of exogenous radiolabelled arachidonic acid, WU-test, circulating endothelial cell count, concentration of platelet factor 4, beta-thromboglobulin, malondialdehyde and the PGI2-synthesis stimulating plasma factor did not show any clear drug-related alteration. It is concluded that infusion of taprostene 25 ng.kg-1.min-1 caused measurable inhibition of platelet function ex vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2111774     DOI: 10.1007/bf00315573

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Platelet half-life in comparison to other in-vivo platelet function parameters such as thromboxane B2, beta-thromboglobulin and platelet factor 4 in patients with atherosclerotic lesions with and without hyperlipoproteinemia.

Authors:  E Strobl-Jäger; P Fitscha; J Kaliman; K Widhalm; H Sinzinger
Journal:  Vasa       Date:  1986       Impact factor: 1.961

2.  Rebound platelet activation during continuous epoprostenol infusion.

Authors:  H Sinzinger; C Leithner; K Silberbauer
Journal:  Lancet       Date:  1984-09-29       Impact factor: 79.321

3.  Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue.

Authors:  J Kaliman; P Fitscha; H Barth; H Sinzinger
Journal:  Prog Clin Biol Res       Date:  1987

4.  Hemodialysis with the stable prostacyclin analogue CG 4203.

Authors:  N Maurin
Journal:  Prog Clin Biol Res       Date:  1987

5.  Thromboxane B2, 6-keto-PGF1 alpha, PGE2, PGF2 alpha, and PGA1 plasma levels in arteriosclerosis obliterans: relationship to clinical manifestations, risk factors, and arterial pathoanatomy.

Authors:  R Jouve; P H Rolland; C Delboy; C Mercier
Journal:  Am Heart J       Date:  1984-01       Impact factor: 4.749

6.  Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications.

Authors:  K K Wu; J C Hoak
Journal:  Thromb Haemost       Date:  1976-06-30       Impact factor: 5.249

7.  Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial.

Authors:  J J Belch; A McKay; B McArdle; P Leiberman; J G Pollock; G D Lowe; C D Forbes; C R Prentice
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

8.  Successful therapy of advanced arteriosclerosis obliterans with prostacyclin.

Authors:  A Szczeklik; R Nizankowski; S Skawinski; J Szczeklik; P Gluszko; R J Gryglewski
Journal:  Lancet       Date:  1979-05-26       Impact factor: 79.321

9.  Platelet sensitivity to antiaggregatory prostaglandins (PGE1,D2,I2) in patients with peripheral vascular disease.

Authors:  P Fitscha; J Kaliman; H Sinzinger
Journal:  Am J Hematol       Date:  1985-05       Impact factor: 10.047

10.  The effects of intravenous ZK36-374, a stable prostacyclin analogue, on normal volunteers.

Authors:  J J Belch; I Greer; M McLaren; A R Saniabadi; S Miller; R D Sturrock; C D Forbes
Journal:  Prostaglandins       Date:  1984-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.